2005PubMedRequires access

[Paget's disease of bone].

Shinjiro Takata

Open publisher page 2 citations

Abstract

Paget's disease of bone (PDB) is a chronic disorder characterized by focal abnormalities of bone turnover. The symptoms of PDB include bone pain, bone deformity, osteoarthritis, and an increase in risk of pathological fracture and neurological problems. PDB is the second most common metabolic bone disease in European countries, although PDB is uncommon in Japan. PDB shows geographical and ethnic clustering. Based on this, two hypotheses of etiology of PDB have been proposed. One hypothesis is that PDB results from a slow virus infection of osteoclasts with paramyxovirus. The other is that PDB is a genetic disease. The development of bisphosphonate has brought major changes to the treatment of PDB. In Japan, etidronate and calcitonin are approved by the Ministry of Health, Labour and Welfare for treating PDB. Risedronate is under development for treating PDB in Japan.

About this research paper

What this paper is about

Paget's disease of bone (PDB) is a chronic disorder characterized by focal abnormalities of bone turnover. The symptoms of PDB include bone pain, bone deformity, osteoarthritis, and an increase in risk of pathological fracture and neurological problems. PDB is the second most common metabolic bone disease in European countries, although PDB is uncommon in Japan. PDB shows geographical and ethnic clustering. Based on this, two hypotheses of etiology of PDB have been proposed. One hypothesis is that PDB results from a slow virus infection of osteoclasts with paramyxovirus. The other is that PDB is a genetic disease. The development of bisphosphonate has brought major changes to the treatment of PDB. In Japan, etidronate and calcitonin are approved by the Ministry of Health, Labour and Welfare for treating PDB. Risedronate is under development for treating PDB in Japan.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Paget's disease of bone (PDB) is a chronic disorder characterized by focal abnormalities of bone turnover. The symptoms of PDB include bone pain, bone deformity, osteoarthritis, and an increase in risk of pathological fracture and neurological problems. PDB is the second most common metabolic bone disease in European countries, although PDB is uncommon in Japan. PDB shows geographical and ethnic clustering. Based on this, two hypotheses of etiology of PDB have been proposed. One hypothesis is that PDB results from a slow virus infection of osteoclasts with paramyxovirus. The other is that PDB is a genetic disease. The development of bisphosphonate has brought major changes to the treatment of PDB. In Japan, etidronate and calcitonin are approved by the Ministry of Health, Labour and Welfare for treating PDB. Risedronate is under development for treating PDB in Japan.

Key concepts: Protein Data Bank (RCSB PDB), Paget's disease of bone, Medicine, Bone remodeling, Protein Data Bank, Etiology, Bone pain, Bioinformatics

Related papers

Back to paper searchBrowse research topicsOriginal source
[Paget's disease of bone]. — Research Paper | ScholarLens